Q1 EPS Forecast for PMV Pharmaceuticals Boosted by Analyst

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) – Stock analysts at HC Wainwright boosted their Q1 2026 earnings estimates for shares of PMV Pharmaceuticals in a report released on Wednesday, November 12th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their previous forecast of ($0.41). The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.65) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PMV Pharmaceuticals in a report on Wednesday, November 5th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, PMV Pharmaceuticals presently has an average rating of “Hold” and an average price target of $5.00.

PMV Pharmaceuticals Stock Up 2.9%

NASDAQ:PMVP opened at $1.42 on Monday. The stock’s 50 day moving average price is $1.39 and its two-hundred day moving average price is $1.27. The firm has a market capitalization of $75.56 million, a price-to-earnings ratio of -0.89 and a beta of 1.54. PMV Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $1.84.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Wednesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40).

Insider Transactions at PMV Pharmaceuticals

In other news, major shareholder Orbimed Advisors Llc sold 1,000,000 shares of the business’s stock in a transaction that occurred on Thursday, October 23rd. The stock was sold at an average price of $1.52, for a total transaction of $1,520,000.00. Following the completion of the sale, the insider owned 4,975,291 shares in the company, valued at $7,562,442.32. The trade was a 16.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.60% of the stock is owned by company insiders.

Institutional Trading of PMV Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. BML Capital Management LLC grew its holdings in PMV Pharmaceuticals by 5.8% in the 3rd quarter. BML Capital Management LLC now owns 5,292,000 shares of the company’s stock valued at $7,409,000 after buying an additional 292,000 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its position in shares of PMV Pharmaceuticals by 3.6% in the third quarter. ArrowMark Colorado Holdings LLC now owns 3,301,341 shares of the company’s stock valued at $4,622,000 after acquiring an additional 113,225 shares during the period. Vanguard Group Inc. grew its stake in shares of PMV Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 2,163,027 shares of the company’s stock valued at $3,028,000 after acquiring an additional 9,427 shares in the last quarter. Acadian Asset Management LLC increased its position in PMV Pharmaceuticals by 0.9% during the second quarter. Acadian Asset Management LLC now owns 2,066,137 shares of the company’s stock worth $2,188,000 after acquiring an additional 18,960 shares during the period. Finally, Stonepine Capital Management LLC increased its position in PMV Pharmaceuticals by 34.2% during the second quarter. Stonepine Capital Management LLC now owns 845,968 shares of the company’s stock worth $897,000 after acquiring an additional 215,785 shares during the period. 90.20% of the stock is owned by institutional investors and hedge funds.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.